Neurosarcoidosis

Patompong Ungprasert, Eric Lawrence Matteson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Neurosarcoidosis occurs in 3% to 10% of patients with sarcoidosis. Cranial neuropathy and meningeal involvement are the most common manifestations, but any part of the nervous system can be affected. Definite diagnosis requires the presence of noncaseating granuloma in the nervous system, although histopathologic confirmation is often not obtainable. Moderate to high dose of glucocorticoids is the main therapy for neurosarcoidosis. Relapse often occurs after the dose of glucocorticoids is tapered down, often necessitating the use of steroid-sparing immunosuppressive agents.

Original languageEnglish (US)
JournalRheumatic Disease Clinics of North America
DOIs
StateAccepted/In press - 2017

Fingerprint

Nervous System
Glucocorticoids
Cranial Nerve Diseases
Immunosuppressive Agents
Sarcoidosis
Granuloma
Steroids
Recurrence
Neurosarcoidosis
Therapeutics

Keywords

  • Clinical manifestation
  • Imaging study
  • Neurosarcoidosis
  • Outcome
  • Sarcoidosis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Neurosarcoidosis. / Ungprasert, Patompong; Matteson, Eric Lawrence.

In: Rheumatic Disease Clinics of North America, 2017.

Research output: Contribution to journalArticle

@article{efa53f6a6fe6400d8ed80a6d658c175e,
title = "Neurosarcoidosis",
abstract = "Neurosarcoidosis occurs in 3{\%} to 10{\%} of patients with sarcoidosis. Cranial neuropathy and meningeal involvement are the most common manifestations, but any part of the nervous system can be affected. Definite diagnosis requires the presence of noncaseating granuloma in the nervous system, although histopathologic confirmation is often not obtainable. Moderate to high dose of glucocorticoids is the main therapy for neurosarcoidosis. Relapse often occurs after the dose of glucocorticoids is tapered down, often necessitating the use of steroid-sparing immunosuppressive agents.",
keywords = "Clinical manifestation, Imaging study, Neurosarcoidosis, Outcome, Sarcoidosis, Treatment",
author = "Patompong Ungprasert and Matteson, {Eric Lawrence}",
year = "2017",
doi = "10.1016/j.rdc.2017.06.008",
language = "English (US)",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Neurosarcoidosis

AU - Ungprasert, Patompong

AU - Matteson, Eric Lawrence

PY - 2017

Y1 - 2017

N2 - Neurosarcoidosis occurs in 3% to 10% of patients with sarcoidosis. Cranial neuropathy and meningeal involvement are the most common manifestations, but any part of the nervous system can be affected. Definite diagnosis requires the presence of noncaseating granuloma in the nervous system, although histopathologic confirmation is often not obtainable. Moderate to high dose of glucocorticoids is the main therapy for neurosarcoidosis. Relapse often occurs after the dose of glucocorticoids is tapered down, often necessitating the use of steroid-sparing immunosuppressive agents.

AB - Neurosarcoidosis occurs in 3% to 10% of patients with sarcoidosis. Cranial neuropathy and meningeal involvement are the most common manifestations, but any part of the nervous system can be affected. Definite diagnosis requires the presence of noncaseating granuloma in the nervous system, although histopathologic confirmation is often not obtainable. Moderate to high dose of glucocorticoids is the main therapy for neurosarcoidosis. Relapse often occurs after the dose of glucocorticoids is tapered down, often necessitating the use of steroid-sparing immunosuppressive agents.

KW - Clinical manifestation

KW - Imaging study

KW - Neurosarcoidosis

KW - Outcome

KW - Sarcoidosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85028333179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028333179&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2017.06.008

DO - 10.1016/j.rdc.2017.06.008

M3 - Article

C2 - 29061245

AN - SCOPUS:85028333179

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

ER -